PD-1 inhibitor maintenance after stem cell transplant for Hodgkin lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether a PD-1 inhibitor (a type of immunotherapy) given after an autologous stem cell transplant can help prevent Hodgkin lymphoma from coming back in people at high risk of relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have Hodgkin lymphoma that came back or didn't respond to treatment, and you have had a stem cell transplant using your own cells as part of your second or later line of therapy.
- Your lymphoma is considered high-risk (for example, it didn't respond to first treatment, relapsed within a year, or had signs of disease on a PET/CT scan before transplant).
- After transplant, a PET/CT scan shows your disease is completely gone or significantly reduced.
- You have recovered your blood counts enough (white blood cells, neutrophils, and platelets above certain levels).
- You are able to take care of yourself (ECOG score 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether pembrolizumab plus brentuximab works better than standard chemotherapy followed by an autologous stem cell transplant for people whose classic Hodgkin lymphoma has come back or did not respond. It may help by improving cancer control before and around stem cell transplant and by comparing outcomes between the two treatment approaches.
This trial tests a combination of two drugs—a PD-1 antibody (which helps the immune system fight cancer) and a JAK inhibitor (which reduces inflammation)—in children ages 6–18 with newly diagnosed classic Hodgkin lymphoma who have never received cancer treatment before. The goal is to see if this combination works better than standard treatments.
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
This trial tests whether doing your own stem cell transplant, followed by polatuzumab, can improve outcomes in people with specific B-cell non-Hodgkin or Hodgkin lymphomas that did not fully respond or has come back. It aims to add a targeted medicine after transplant to help control the lymphoma.
This Phase 2 study tests an auto (self) stem cell transplant for people with certain types of non-Hodgkin lymphoma or Hodgkin lymphoma who respond to chemotherapy (they are “chemo-sensitive”). It may help some patients get a deeper or longer remission by resetting the bone marrow after high-dose treatment.
This trial tests a new way to prevent graft-versus-host disease (GVHD) after a stem cell transplant in people who have already received PD-1 immunotherapy. The goal is to make the transplant safer and more effective.
Hear when a new Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.